

Cell and Gene Therapy Manufacturing  
INVESTMENT OPPORTUNITY  
Biotechnology and Pharma




# Biotechnology and Pharma

## Cell and Gene Therapy Manufacturing

**OPPORTUNITY DESCRIPTION:** CGT encompasses a group of novel therapies involving either the manipulation of cells to improve the immune system (cell therapy), or the transfer of genetic material to treat disease (gene therapy). This opportunity addresses the manufacturing of CAR-T and gene therapies<sup>2</sup>

### DEMAND

MIDDLE EAST MARKET SIZE, USD M



### INVESTMENT OVERVIEW

#### INVESTMENT HIGHLIGHTS

- Expected Investment size of USD: 25M – 50M
- Manufacturing capacity: 500 – 5000 doses annually
- Expected IRR: 15 – 20%
- Job Creation: ~50 high skilled postgraduate level jobs (e.g., manufacturing science and tech., assay development, regulatory affairs), with average salaries of \$70K+ p.a.
- GDP Impact USD: 17M<sup>2</sup>
- Location (Examples): KFSH-RC, NEOM, Dammam

#### VALUE PROPOSITION

- Commitment to biopharma manufacturing across multiple entities and areas incl. viral vectors, mRNA, and mAbs
- Strong network of specialized clinical providers, with KFSH- RC the largest specialized center in the region and has a dedicated medical genetics department
- Dedicated push on enhancing pharma supply security, with efforts across entities and programs including Industrial Clusters and National Industrial Development Program
- Robust set of ecosystem entities, such as NHIC, SNIH, SFDA, and NUPCO, all of which contribute to strong research, regulatory and execution capabilities required for CGT

#### KEY DEMAND DRIVERS

- Increasing incidence of cancer, chronic and rare genetic cases (genetic and lifestyle related), driving CGT interest
- Above average occurrences of auto-sosomal recessive disorders, e.g. congenital heart disease, sickle-cell anemia, which can specifically be targeted by gene therapies
- KSA is being developed as a hub for innovative treatments, driving regional demand

### MARKET OVERVIEW

#### EQUIPMENT AND REAGENTS

- |  |  |
|--|--|
| <b>Gene Therapy</b> <ul style="list-style-type: none"> <li>Cells (e.g., HEK293T cells)</li> <li>Media (for cell cultivation)</li> <li>Cell handling system</li> <li>Chamber</li> <li>Bioreactor</li> <li>GMP grade plasmids</li> <li>Transfection Reagents</li> <li>Harvesting system</li> <li>Clarification, purification, formulation, and filtration systems</li> </ul> | <b>Cell Therapy</b> <ul style="list-style-type: none"> <li>Cell isolation and activation systems</li> <li>Viral vectors</li> <li>Transduction reagent</li> <li>Cell handling systems</li> <li>Chambers and flasks</li> <li>Harvesting system</li> <li>Cryobags and freezing systems</li> </ul> |
|--|--|

#### GLOBAL TRENDS

- Oncology, CNS disorders and infectious diseases account for majority of CGT clinical trials, with 2,093 clinical trials in progress globally and 200 in phase 3 (as of June 2022)
- Demand for viral vectors outstripping supply, with 70% of clinical trials in progress requiring viral vectors – low supply driven by complex manufacturing methods and shortage of manufacturing capacity
- Increased focus on improving CGT manufacturing cost and time, through improved supply chains, industrial collaboration and iterative improvements to reduce costs

<sup>1</sup> GDP impact solely associated with establishment of the R&D facility. Larger GDP impacts are associated with CGT as a driver of additional research, improved health adjusted life years and other wider health economic impacts

<sup>2</sup> This opportunity addresses CGT manufacturing/ product processing specifically, and does not include clinical delivery activities



### SUPPLY

#### SCALABILITY AND LOCALIZATION

Grade: Low Medium High


- Supported by multiple biotech manufacturing efforts/ hubs across KSA, presenting opportunities for localization, increasing number of doses produced and introducing additional CGT products
- Notable efforts in KSA to increase security of pharma supply and localize manufacturing
- Ability to serve cumulative demand of GCC, Organization of Islamic Countries (OIC) and MENA as regional pioneer of CGT

#### CURRENT ACTIVITIES


- Key treatment center involved in delivering CGT (specifically CAR-T therapy) is King Faisal Specialist Hospital and Research Center (KFSH-RC), including clinical trials delivery

#### VALUE CHAIN

##### Gene Therapy



##### Cell Therapy



#### KEY STAKEHOLDERS





### ENABLING FACTORS

#### ENABLERS & INCENTIVES

- Fixed incentives in place for pharma industry, and potential for customized incentive packages based on discussions with MISA
- Access to established specialized provider network for manufacturing sites (e.g., KFSH-RC)

#### COST OF DOING BUSINESS IN KSA



# DEFINITIONS

#	SCORECARD SECTION	DEFINITIONS
1	Market size	Size of market in value/volume in KSA and/or Region (MENA/GCC) covering future projections based on available estimates from published /government sources
2	Business drivers	A select number of factors that will influence future demand for the related product/service
3	Investment highlights	An overview of key financial metrics summarizing the investment opportunity along with the expected return based on the suggested investment size
4	Value proposition	Summary of key differentiators that position KSA as a strategic choice over other regional/global peers
5	Market readiness	An overview of KSA market structure, market maturity and level of participation by local and global players
6	Global trends	Latest business developments within the sector/product category
7	Scalability and localization	Ease of scaling the business across the value chain or into new adjacent products or geographies that would maximize the opportunity's investment returns and the ability and potential to locally manufacture the product and its components
8	Import dependency	An overview of the countries from which Saudi Arabia is importing the product and their value/volume and share in total imports
9	Value chain analysis	The process or activities that would potentially need to be carried out to deliver the underlying product or service
10	Key stakeholders	Government institutions, organizations, and/or authorities that participate or influence the market for the underlying product/service
11	Enablers	Factors that enable investment in the underlying opportunity
12	Cost of doing business in KSA	Key factors that position KSA as a competitive destination for investment in the region. Productivity adjusted wages do not include cost of \$1.23/hour towards annual recurring charges including work permit, resident identity (iqama) and health insurance

# DISCLAIMER

- This material must be used only to access information, and the information must not be construed, under any circumstances, explicitly or implicitly, as an offer to sell or a solicitation to buy or sell or trade in any opportunity herein mentioned.
- Ministry of Investment (MISA) has no undertaking to update these materials after the date, with the understanding that such information may become outdated or inaccurate.
- Mentioned information in this material is obtained from reliable sources but its accuracy and reliability are in no way guaranteed. No guarantee of any kind is tacit or explicit when projections of future conditions are attempted. MISA has used public/or confidential data and assumptions and has not independently verified the data and assumptions used in the analyses. Changes in underlying data or operating assumptions will clearly impact the analyses and conclusions.
- The financial evaluations, projected market and financial information, and conclusions contained in these materials are based upon standard methodologies, are not definitive projections, and are not guaranteed by MISA
- The content of this material must not be construed as an implied promise or guarantee for profit or limited loss express or implied by or from MISA or any of its officers, directors, employees and affiliates. All mentioned investments in this material are subject to risk, which should be considered prior to making any investment decisions
- MISA shall have no liability whatsoever to any third party, and hereby any third party waives any rights and claims it may have at any time against MISA with regard to this material, any services or other materials, including the accuracy or completeness thereof.

CONNECT WITH US FOR MORE DETAILS:

PharmaandBiotech@misa.gov.sa

investsaudi.sa



@investsaudi

